عرض بسيط للتسجيلة

المؤلفKheraldine, Hadeel
المؤلفGupta, Ishita
المؤلفCyprian, Farhan Sachal
المؤلفVranic, Semir
المؤلفAl-Farsi, Halema F
المؤلفMerhi, Maysaloun
المؤلفDermime, Said
المؤلفAl Moustafa, Ala-Eddin
تاريخ الإتاحة2024-04-28T08:28:45Z
تاريخ النشر2024-03-02
اسم المنشورCancer Cell International
المعرّفhttp://dx.doi.org/10.1186/s12935-023-03195-z
الاقتباسKheraldine, H., Gupta, I., Cyprian, F. S., Vranic, S., Al-Farsi, H. F., Merhi, M., ... & Al Moustafa, A. E. (2024). Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways. Cancer Cell International, 24(1), 1-15.
الرقم المعياري الدولي للكتاب1475-2867
معرّف المصادر الموحدhttp://hdl.handle.net/10576/54305
الملخصRecent investigations have reported the benefits of using a tyrosine kinase inhibitor, dasatinib (DA), as well as programmed death-ligand 1 (PD-L1) inhibitors in the management of several solid tumors, including breast cancer. Nevertheless, the outcome of the combination of these inhibitors on HER2-positive breast cancer is not explored yet. Herein, we investigated the impact of DA and PD-L1 inhibitor (BMS-202) combination on HER2-positive breast cancer cell lines, SKBR3 and ZR75. Our data reveal that the combination significantly inhibits cell viability of both cancer cell lines as compared to monotreatment. Moreover, the combination inhibits epithelial-mesenchymal transition (EMT) progression and reduces cancer cell invasion by restoring E-cadherin and β-catenin expressions and loss of vimentin, major biomarkers of EMT. Additionally, the combination reduces the colony formation of both cell lines in comparison with their matched control. Also, the combination considerably inhibits the angiogenesis of the chorioallantoic membrane model compared with monotreatment. Molecular pathway analysis of treated cells shows that this combination blocks HER2, AKT, β-catenin, and JNK1/2/3 activities. Our findings implicate that a combination of DA and BMS-202 could have a significant impact on the management of HER2-positive breast cancer.
راعي المشروعThis work was funded by Qatar University, grant number # QUCP-CMED-22/23–529.
اللغةen
الناشرSpringer Nature
الموضوعDasatinib
EMT
HER2-positive breast cancer
Invasion
PD-1/PD-L1
العنوانTargeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways.
النوعArticle
الصفحات1-15
رقم العدد1
رقم المجلد24
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة